2. Cell Cycle/DNA Damage Cytoskeleton
  3. Mps1
  4. Luvixasertib

CFI-402257 est un inhibiteur de TTK/Mps1 qui est hautement sélectif et oralement biodisponible avec un IC50 de 1,7 nM pour le TTK in vitro. CFI-402257 a une activité anticancéreuse.

CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity.

For research use only. We do not sell to patients.

Luvixasertib Chemical Structure

Luvixasertib Chemical Structure

CAS No. : 1610759-22-2

Size Price Stock Quantity
5 mg USD 330 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Luvixasertib:

Luvixasertib Related Antibodies

Top Publications Citing Use of Products

    Luvixasertib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2019 Feb;9(2):230-247.  [Abstract]

    Western analysis of protein expression in different concentrations of CFI-402257 treatment.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity[1].

    IC50 & Target

    IC50: 1.7 nM (TTK in vitro)[1].
    Cellular Effect
    Cell Line Type Value Description References
    HCT-116 GI50
    0.04 μM
    Compound: 22
    Growth inhibition of human HCT116 cells measured after 5 days by sulforhodamine B assay
    Growth inhibition of human HCT116 cells measured after 5 days by sulforhodamine B assay
    		[PMID: 27437075]
    MDA-MB-468 GI50
    0.071 μM
    Compound: 22
    Growth inhibition of human MDA-MB-468 cells measured after 5 days by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells measured after 5 days by sulforhodamine B assay
    		[PMID: 27437075]
    OVCAR-3 GI50
    0.1 μM
    Compound: 22
    Growth inhibition of human OVCAR3 cells measured after 5 days by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells measured after 5 days by sulforhodamine B assay
    		[PMID: 27437075]
    In Vitro

    CFI-402257 is highly selective to TTK. CFI-402257 is tested against a panel of human kinases at 1 μM and inhibits none of the 262 kinases tested. CFI-402257 is a potent inhibitor of cell growth[1].
    CFI-402257 (200 nM, 6 h) causes a massive increase in chromosome missegregations[2].
    CFI-402257 (0, 50 or 100 nM) induces a dose-dependent dysregulation of the cell cycle, resulting in an increase in the frequency of cells exhibiting an aneuploid DNA content[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Luvixasertib Related Antibodies

    Cell Cycle Analysis[2]

    Cell Line: HCT116 cells.
    Concentration: 0 nM, 50 nM, 100 nM, 300 nM, 1000 nM, 3000 nM.
    Incubation Time: 48 hours.
    Result: Resulted in an increase in the frequency of cells exhibiting an aneuploid DNA content.

    Western Blot Analysis[2]

    Cell Line: HCT116 cells.
    Concentration: 0 nM, 50 nM or 100 nM.
    Incubation Time: 8, 16, 24 and 48 hours.
    Result: CFI-402257-induced aneuploidy was accompanied by a progressive accumulation of apoptotic cells that were detectable as early as 16 h following treatment.
    In Vivo

    CFI-402257 given orally QD shows dose-dependent activity in mice with established tumors from xenografted MDA-MB-231 human TNBC cells and MDA-MB-468 human TNBC cells in mice. CFI-402257 demonstrates antitumor activity in a platinum-resistant PDX model of high-grade serous ovarian cancer[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Xenografted MDA-MB-231 human TNBC cells and MDA-MB-468 human TNBC cells in mice[2].
    Dosage: 5, 6 mg/kg.
    Administration: Oral gavage, daily.
    Result: Xenografted MDA-MB-231 human TNBC cells: 5 mg/kg, tumor growth inhibition (TGI) = 74%; 6 mg/kg, TGI = 89%.
    Xenografted MDA-MB-468 human TNBC cells: 5 mg/kg, tumor growth inhibition (TGI) = 75%; 6 mg/kg, TGI = 94%.
    Animal Model: PDX model of high-grade serous ovarian cancer[2].
    Dosage: 6.5, 7.5 mg/kg.
    Administration: Oral gavage, daily.
    Result: 6.5 mg/kg, tumor growth inhibition (TGI) = 61%; 7.5 mg/kg, TGI = 97%.
    Molecular Weight

    498.58

    Formula

    C28H30N6O3
    CAS No.
    Appearance

    Solid

    SMILES

    CC1=CC(C2=C3N=C(OC4=CN=CC=C4)C=C(NC[C@@H]5C[C@@](O)(C)C5)N3N=C2)=CC=C1C(NC6CC6)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 1.67 mg/mL (3.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0057 mL 10.0285 mL 20.0570 mL
    5 mM --- --- ---
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.56%

    SDS (251 KB)

    COA (252 KB) LCMS (120 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.0057 mL 10.0285 mL 20.0570 mL 50.1424 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Luvixasertib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Luvixasertib1610759-22-2CFI-402257CFI402257CFI 402257Mps1Monopolar spindle 1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Luvixasertib
    Cat. No.:
    HY-101340
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.